Baxter International BAX · USD
Health Care · Health Care Equipment & Supplies · US listing · 🇺🇸 United States
S&P 500
26.41
+2.40%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Baxter International
From its filings with the US Securities and Exchange Commission
Baxter International is based in Deerfield, Illinois and is incorporated in Delaware. Its shares trade on NYSE under the ticker BAX. It is a member of the S&P 500. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $11.24bn and a net loss of $957.0m. At that date it held total assets of $20.05bn and shareholders' equity of $6.13bn.
Baxter International Inc., through our subsidiaries, provides a broad portfolio of essential healthcare products, including sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices. These products are used by hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, kidney dialysis centers and patients at home under physician supervision. Our global footprint and the critical nature of our products and services play a key role in expanding access to healthcare in emerging and developed countries. As of December 31, 2025, after giving effect to the sale of our Kidney Care business (as discussed below), we manufactured products in over 20 countries and sold them in over 100 countries.
On August 12, 2024, we entered into an Equity Purchase Agreement (EPA) with certain affiliates of Carlyle Group Inc. (Carlyle) to sell our Kidney Care business. That business, which is now known as Vantive Health LLC (Vantive) is comprised of our former Kidney Care segment. On January 31, 2025, we completed the sale of our Kidney Care business to Carlyle for an aggregate purchase price of $3.80 billion in cash, subject to certain closing cash, working capital and debt adjustments.
Quoted from its 10-K, filed 12 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 15 May 1961
- Employees
- 37,500
- Website
- baxter.com ↗
- Head office
- ONE BAXTER PARKWAY, DEERFIELD, IL, 60015
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. D. Brent ShaferNon-Executive Chairman of the Board, since 2022$386,986
- Mr. Andrew HiderPresident, Chief Executive Officer, Director, since 2025
- Mr. Joel GradeChief Financial Officer, Executive Vice President$6.5m
- Ms. Heather KnightChief Operating Officer, Executive Vice President, Interim Group President, Medical Products and Therapies$6.6m
- Dr. Jeanne MasonChief Human Resources Officer, Executive Vice President$4.1m
- Mr. David RosenbloomExecutive Vice President, General Counsel$5.6m
- Mr. James BorziExecutive Vice President and Chief Supply Chain Officer
- Mr. Reazur RasulExecutive Vice President, Group President - Healthcare Systems and Technologies
- Mr. Alok SonigExecutive Vice President, Group President - Pharmaceuticals$5.3m
- Ms. Nancy SchlichtingLead Independent Director$369,521
- Mr. William AmpofoIndependent Director$324,986
- Mr. Jeffrey CraigIndependent Director$173,540
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 77
- Environment
- 69
- Social
- 80
- Governance
- 83
- Direct emissions (scope 1)
- 351,733 t
- Energy emissions (scope 2)
- 384,454 t
- Value chain emissions (scope 3)
- 4,915,054 t
- Women in the workforce
- 47%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong Market Position: Baxter International Inc holds a significant market share in the healthcare industry, especially in the field of medical devices and pharmaceuticals.
- Diverse Product Portfolio: The company offers a wide range of products, including renal therapies, anesthesia products, surgical equipment, and pharmaceuticals, which helps in catering to different customer needs.
- Global Presence: Baxter has a strong global presence, with operations in multiple countries, allowing it to capitalize on emerging markets and diverse customer base.
Weaknesses
- Product Recalls: Baxter has faced product recalls in the past, which have affected its reputation and consumer confidence. The company needs to focus on improving its quality control processes.
- Dependence on Key Customers: Baxter has a significant reliance on a few key customers for a substantial portion of its revenue. This dependency poses a risk if those customers choose to shift to competitors or face financial difficulties.
- High R&D Costs: The research and development expenses of Baxter are substantial, and the company needs to ensure that the investments result in successful product innovations and market differentiation.
Opportunities
- Growing Aging Population: With the global population aging, there is a growing demand for healthcare products and services, creating an opportunity for Baxter to expand its customer base.
- Increasing Healthcare Expenditure: Governments and individuals are allocating more funds towards healthcare expenditure, providing an opportunity for Baxter to generate higher sales and revenues.
- Technological Advancements: Advancements in technology, such as telemedicine and digital health platforms, present opportunities for Baxter to develop innovative products and solutions to meet the changing needs of healthcare providers and patients.
Threats
- Intense Competition: Baxter operates in a highly competitive industry, facing competition from both established players and new entrants. This competition can impact market share and pricing power.
- Regulatory Compliance: Compliance with stringent regulations and varying healthcare policies across different countries can create challenges for Baxter in terms of product approvals, pricing, and market access.
- Economic Factors: Global economic instability, currency fluctuations, and healthcare budget cuts in certain regions can pose threats to Baxter's financial performance and growth prospects.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.